SCHEMBL24660486

SCHEMBL24660486

C[C@H](NC(=O)OC(C)(C)C)c1nc(-c2ccnc(CO)c2)no1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KCNT1 Q5JUK3 10/20 0.51
▸ KCNQ1 P51787 1/20 0.46
▸ KCNH2 Q12809 1/20 0.46
▸ CACNA1C Q13936 1/20 0.46
▸ SCN5A Q14524 1/20 0.46
▸ KCNMB1 Q16558 1/20 0.46
▸ KCNT2 Q6UVM3 1/20 0.46
▸ S1PR1 P21453 1/20 0.46
▸ S1PR3 Q99500 1/20 0.46
▸ PPARD Q03181 3/20 0.45
▸ PPARA Q07869 3/20 0.45
▸ ACACB O00763 4/20 0.45
▸ TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28710641 1.00 KCNT1 (0.51) KCNT1KCNQ1KCNH2CACNA1CSCN5A
Hydrochloric Acid SCHEMBL28701518 0.99 KCNT1 (0.51) KCNT1KCNQ1KCNH2CACNA1CSCN5A
Hydrochloric Acid SCHEMBL28701517 0.99 KCNT1 (0.51) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL24660546 0.90 KCNT1 (0.63) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL24660793 0.89 KCNT1 (0.53) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL24660803 0.88 KCNT1 (0.53) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL24660721 0.86 KCNT1 (0.59) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL22637519 0.86 KCNT1 (0.59) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL24660174 0.86 KCNT1 (0.48) KCNT1KCNQ1KCNH2CACNA1CSCN5A
SCHEMBL24660575 0.86 KCNT1 (0.59) KCNT1KCNQ1KCNH2CACNA1CSCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2022-08-18 — — US disclosed
CN-114269340-A KCNT1 inhibitors and methods of use 普拉克西斯精密药物股份有限公司 2022-04-01 — — CN disclosed
EP-3962481-A1 KCNT1 INHIBITORS AND METHODS OF USE Praxis Precision Medicines, Inc. (US) 2022-03-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220259193-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 KCNT1 1/4885KCNQ1 4/4885KCNH2 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback